Seroquel XR or IR and Thinking Skills in Schizophrenia
About this title
Read the official source — NCT01213836Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Vienna and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 75
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Austria, Denmark, Germany, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT01213836
- Official title
Show the full official title
A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR®) Dosed Twice Daily and Quetiapine Fumarate Extended Release (Seroquel XR®) Dosed Once Daily in the Evening in Patients With Stable Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Vienna, Austria · Middelfart, Denmark · Berlin, Germany
17 more locations
- Bochum, Germany
- Hamburg, Germany
- München, Germany
- Rottweil, Germany
- Giarre, Italy
- Genova, Italy
- Lido di Camaiore, Italy
- Barakaldo (vizcaya), Italy
- Tivoli, Italy
- Sant'Arsenio, Italy
- Sassari, Italy
- Borgomanero, Italy
- Catania, Italy
- Roma, Italy
- Torre Annunziata, Italy
- Salamanca, Spain
- Zamora, Spain
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Seroquel XR- quetiapine fumarate extended release, Seroquel IR - quetiapine fumarate, Placebo matching Seroquel XR and Placebo matching Seroquel IR.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
